report published by Value Market Research provides a detailed market analysis comprising of market size, share, value, growth and trends for the period 2021-2028. The report encompasses data regarding market share and recent developments by key players. Moreover, this market report also covers regional and country market in detail.
Continued investment in viral and gene therapies from clinical to commercial scale fuels the growth of the global viral vector manufacturing services market. Gene and cell therapies are rapidly advancing to late-stage clinical trials and commercialization. There is a growing need for flexible, high-quality advanced viral vector development and manufacturing services to provide the highest level of patient safety and reliability. Gene and cell therapy (GCT) can potentially transform medicine, providing long term and potentially curative treatment options for a wide range of diseases. Recognizing the growing need for viral vector production services on the development and commercial scale, players are expanding their capacity. However, there are a limited number of biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) with the resources in place across all stages of the drug development cycle. Responding to this, companies are widening their range of offerings by adding viral vector and gene-therapy services. Alongside a growing manufacturing footprint, the company has found its services in demand during the novel coronavirus outbreak.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of viral vector manufacturing services.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the viral vector manufacturing services market include Novasep, Spark Therapeutics, Lonza Pharma & Biotech, Takara Bio, Sartorius, ABL, Inc., Fujifilm Diosynth Biotechnologies, Cobra Biologics, Sanofi, Finvector, uniQure. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
The entire viral vector manufacturing services market has been sub-categorized into product and application. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
· Retroviral Vectors
· Adenoviral Vectors
· Adeno-associated Viral Vectors
· Pharmaceutical and Biopharmaceutical Companies
· Research Institutes
This section covers regional segmentation which accentuates on current and future demand for viral vector manufacturing services market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Browse Global Viral Vector Manufacturing Services Market Research Report with detailed TOC at